Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance

Biomaterials

Volumn 91, Issue , 2016, Pages 44-56

  Liu, Juan ^a   Wei, Tuo ^a   Zhao, Jing ^a   Huang, Yuanyu ^b   Deng, Hua ^a   Kumar, Anil ^a   Wang, Chenxuan ^a   Liang, Zicai ^b   Ma, Xiaowei ^a   Liang, Xing Jie ^a  

^a NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Aptamer; Cancer therapy; Drug delivery; Drug resistance; Self assembly

Indexed keywords

BIOCHEMISTRY; CELLS; CHEMOTHERAPY; CYTOLOGY; DISEASES; DNA; DRUG DELIVERY; DRUG THERAPY; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; OLIGONUCLEOTIDES; SELF ASSEMBLY; TUMORS;

APTAMERS; CANCER THERAPY; DOUBLE-STRANDED DNA (DS-DNA); DRUG DELIVERY STRATEGIES; DRUG RESISTANCE; HUMAN BREAST CANCER CELLS; THREE-DIMENSIONAL NANOSTRUCTURES; THREE-DIMENSIONAL STRUCTURE;

NANOSTRUCTURES;

APTAMER; DOUBLE STRANDED DNA; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; NANOPARTICLE; ANTINEOPLASTIC ANTIBIOTIC; DRUG CARRIER; GUANINE QUADRUPLEX; INTERCALATING AGENT; NUCLEOLIN; PHOSPHOPROTEIN; RNA BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CARDIOTOXICITY; CELL CYCLE ARREST; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG RELEASE; DRUG UPTAKE; FEMALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; BREAST; BREAST NEOPLASMS; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; MCF-7 CELL LINE; METABOLISM; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; PATHOLOGY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APTAMERS, NUCLEOTIDE; BASE SEQUENCE; BREAST; BREAST NEOPLASMS; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; G-QUADRUPLEXES; HUMANS; INTERCALATING AGENTS; MCF-7 CELLS; MICE, INBRED BALB C; MODELS, MOLECULAR; NANOPARTICLES; PHOSPHOPROTEINS; RNA-BINDING PROTEINS;

EID: 84961970988     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.03.013     Document Type: Article

References (46)

1. Shieh Y.A., Yang S.J., Wei M.F., Shieh M.J. Aptamer-based tumor-targeted drug delivery for photodynamic therapy. ACS Nano 2010, 4:1433-1442.
2. Ireson C.R., Kelland L.R. Discovery and development of anticancer aptamers. Mol. Cancer Ther. 2006, 5:2957-2962.
3. Bagalkot V., Farokhzad O.C., Langer R., Jon S. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew. Chem. Int. Ed. 2006, 45:8149-8152.
4. Mayer G. The chemical biology of aptamers. Angew. Chem. Int. Ed. 2009, 48:2672-2689.
5. Guo J., Gao X., Su L., Xia H., Gu G., Pang Z., et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 2011, 32:8010-8020.
6. Mayer G., Pofahl M., Schöler K.M., Haßel S. Cell-specific Aptamers for Nano-medical Applications. Nucleic Acid Nanotechnology 2014, 261-283. Springer.
7. Bates P.J., Laber D.A., Miller D.M., Thomas S.D., Trent J.O. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol. 2009, 86:151-164.
8. Zhu G., Zheng J., Song E., Donovan M., Zhang K., Liu C., et al. Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics. Proc. Natl. Acad. Sci. 2013, 110:7998-8003.
9. Teng Y., Girvan A.C., Casson L.K., Pierce W.M., Qian M., Thomas S.D., et al. AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res. 2007, 67:10491-10500.
10. Soundararajan S., Chen W., Spicer E.K., Courtenay-Luck N., Fernandes D.J. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res. 2008, 68:2358-2365.
11. Charoenphol P., Bermudez H. Aptamer-targeted DNA nanostructures for therapeutic delivery. Mol. Pharm. 2014, 11:1721-1725.
12. Ko H.Y., Lee J.H., Kang H., Ryu S.H., Song I.C., Lee D.S., et al. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J. Nucl. Med. 2010, 51:98-105.
13. Que-Gewirth N., Sullenger B. Gene therapy progress and prospects: RNA aptamers. Gene Ther. 2007, 14:283-291.
14. Wu J., Song C., Jiang C., Shen X., Qiao Q., Hu Y. Nucleolin targeting AS1411 modified protein nanoparticle for antitumor drugs delivery. Mol. Pharm. 2013, 10:3555-3563.
15. Dam D.H., Lee R.C., Odom T.W. Improved in vitro efficacy of gold nanoconstructs by increased loading of G-quadruplex aptamer. Nano Lett. 2014, 14:2843-2848.
16. Soundararajan S., Wang L., Sridharan V., Chen W., Courtenay-Luck N., Jones D., et al. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells. Mol. Pharmacol. 2009, 76:984-991.
17. Gissberg O., Zaghloul E.M., Lundin K.E., Nguyen C.-H., Landras-Guetta C., Wengel J., et al. Delivery, effect on cell viability, and plasticity of modified aptamer constructs. Nucleic Acid Ther. 2016, 10.1089/nat.2015.0592.
18. 2 gas induced drug release from pH-sensitive liposome to circumvent doxorubicin resistant cells. Chem. Commun. 2012, 48:4869-4871.
19. Wei T., Liu J., Ma H., Cheng Q., Huang Y., Zhao J., et al. Functionalized nanoscale micelles improve drug delivery for cancer therapy in vitro and in vivo. Nano Lett. 2013, 13:2528-2534.
20. Ren Y., Wang Y., Zhang Y., Wei D. Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide- doxorubicin conjugate in vitro and in vivo. Mol. Pharm. 2008, 5:579-587.
21. Wang F., Wang Y.-C., Dou S., Xiong M.-H., Sun T.-M., Wang J. Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano 2011, 5:3679-3692.
22. Chang M., Yang C.-S., Huang D.-M. Aptamer-conjugated DNA icosahedral nanoparticles as a carrier of doxorubicin for cancer therapy. ACS Nano 2011, 5:6156-6163.
23. Min K., Jo H., Song K., Cho M., Chun Y.-S., Jon S., et al. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers. Biomaterials 2011, 32:2124-2132.
24. Dong X., Mattingly C.A., Tseng M.T., Cho M.J., Liu Y., Adams V.R., et al. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res. 2009, 69:3918-3926.
25. Liu J., Huang Y., Kumar A., Tan A., Jin S., Mozhi A., et al. pH-Sensitive nano-systems for drug delivery in cancer therapy. Biotechnol. Adv. 2014, 32:693-710.
26. Yan Y., Björnmalm M., Caruso F. Particle carriers for combating multidrug-resistant Cancer. ACS Nano 2013, 7:9512-9517.
27. Pan L., Liu J., He Q., Wang L., Shi J. Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles. Biomaterials 2013, 34:2719-2730.
28. Reyes-Reyes E.M., Teng Y., Bates P.J. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res. 2010, 70:8617-8629.
29. Campolongo M.J., Tan S.J., Xu J., Luo D. DNA nanomedicine: engineering DNA as a polymer for therapeutic and diagnostic applications. Adv. Drug Deliv. Rev. 2010, 62:606-616.
30. He Y., Ye T., Su M., Zhang C., Ribbe A.E., Jiang W., et al. Hierarchical self-assembly of DNA into symmetric supramolecular polyhedra. Nature 2008, 452:198-201.
31. Douglas S.M., Dietz H., Liedl T., Högberg B., Graf F., Shih W.M. Self-assembly of DNA into nanoscale three-dimensional shapes. Nature 2009, 459:414-418.
32. Lo P.K., Karam P., Aldaye F.A., McLaughlin C.K., Hamblin G.D., Cosa G., et al. Loading and selective release of cargo in DNA nanotubes with longitudinal variation. Nat. Chem. 2010, 2:319-328.
33. Wang K., You M., Chen Y., Han D., Zhu Z., Huang J., et al. Self-assembly of a bifunctional DNA carrier for drug delivery. Angew. Chem. Int. Ed. 2011, 50:6098-6101.
34. Huo S., Jin S., Ma X., Xue X., Yang K., Kumar A., et al. Ultrasmall gold nanoparticles as carriers for nucleus-based gene therapy due to size-dependent nuclear entry. ACS Nano 2014, 8:5852-5862.
35. Kaul G., Amiji M. Cellular interactions and in vitro DNA transfection studies with poly (ethylene glycol)-modified gelatin nanoparticles. J. Pharm. Sci. 2005, 94:184-198.
36. Jiang Q., Song C., Nangreave J., Liu X., Lin L., Qiu D., et al. DNA origami as a carrier for circumvention of drug resistance. J. Am. Chem. Soc. 2012, 134:13396-13403.
37. Lee J.B., Hong J., Bonner D.K., Poon Z., Hammond P.T. Self-assembled RNA interference microsponges for efficient siRNA delivery. Nat. Mater. 2012, 11:316-322.
38. Mandelkern M., Elias J.G., Eden D., Crothers D.M. The dimensions of DNA in solution. J. Mol. Biol. 1981, 152:153-161.
39. Hovanessian A.G., Puvion-Dutilleul F., Nisole S., Svab J., Perret E., Deng J.-S., et al. The cell-surface-expressed nucleolin is associated with the actin cytoskeleton. Exp. Cell Res. 2000, 261:312-328.
40. Ginisty H., Sicard H., Roger B., Bouvet P. Structure and functions of nucleolin. J. Cell Sci. 1999, 112:761-772.
41. Xu X., Hamhouyia F., Thomas S.D., Burke T.J., Girvan A.C., McGregor W.G., et al. Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides. J. Biol. Chem. 2001, 276:43221-43230.
42. Wesierska-Gadek J., Gueorguieva M., Herbacek I., Ranftler C. Effect of distinct anticancer drugs on the phosphorylation of p53 protein at serine 46 in human MCF-7 breast cancer cells. Ann. N. Y. Acad. Sci. 2007, 1095:45-52.
43. Sherr C.J. Cancer cell cycles. Science 1996, 274:1672-1677.
44. Garrett M.D. Cell cycle control and cancer. Curr. Sci. - Bangalore 2001, 81:515-522.
45. Shah M.A., Schwartz G.K. Cell cycle-mediated drug resistance an emerging concept in cancer therapy. Clin. Cancer Res. 2001, 7:2168-2181.
46. Liu J., Yu M., Zhou C., Yang S., Ning X., Zheng J. Passive tumor targeting of renal-clearable luminescent gold nanoparticles: long tumor retention and fast normal tissue clearance. J. Am. Chem. Soc. 2013, 135:4978-4981.